SEC Form 4 · accession 0001238303-26-000002
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph J Larosa
Officer — EVP General Counsel and Secret
Period of report
Aug 19, 2026
Accepted (ET)
Aug 21, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 19, 2026 | M | 12,282 | $381.92 | A | 45,392 | D | |
| Common Stock | Aug 19, 2026 | F | 9,019 | $830.15 | D | 36,373 | D | |
| Common Stock | holding | — | — | — | 3,402 | I | By 2024 GRAT | |
| Common Stock | holding | — | — | — | 5,407 | I | By 2025 GRAT | |
| Common Stock | holding | — | — | — | 413 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $381.92 | Aug 19, 2026 | M | 12,282 | D | — | Dec 16, 2026 | Common Stock | 12,282 | 12,283 | D |
Explanation of responses
- F1The stock option award vested in four equal annual installments, commencing one year after the date of grant.